Background: Hepatocellular carcinoma makes up 75%-85% of all primary liver cancers and is the fourth most common cause of cancer related death worldwide. The aim of this study was to screen for hepatocellular carcinoma in hepatic patients who received direct acting antiviral drugs using different imaging modalities. Methods: This was a cross sectional study included 50 patients who were hepatic and received Direct Acting Antiviral '' DAA'' and were carried out at radiology department in Elobour Hospital for Health Insurance after obtaining written informed consent from all patients. Results: There were 31(62%) male, 19(38%) female, the mean age 52.28 years old with range (39-65), 35(70%) urban, 15(30%) rural. There were (70%) with duration of illness ≤ 5 years, (30%) with > 5 years, (100%) with DAA, (90%) easy to treat, (10%) difficult to treat. There were 35(70%) with average liver, 14(28%) with shrunken liver, 1(2%) with enlarged liver, 13(26%) with Bright pattern, 34(68%) with cirrhotic, 3(6%) with coarse bright, the mean P.V diameter 14.68(± 2.51 SD) with range (9-17).There were (100%) with Single focal lesion in RT lobe, the mean size 4.47with range (3.6-5.6), (33.3%) Isochoric, (33.3%) with Hypo echoic, (33.3%) with Hyper echoic, (66.7%) with malignancy. There were 3(100%) with typical CT enhancement, 1(33.3%) with P.V thrombosis. There was no one with Affection on liver vascular, no one with intrahepatic biliary radicles, no one with L.N in porta hepatis. Conclusion: Based on our findings, we recommend for close imaging evaluations after DAA in cirrhotic patients.